Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, Binckebanck A, Schleyer E, Gökbuget N, Wolff T, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG. Pfeifer H, et al. Among authors: binckebanck a. Clin Cancer Res. 2003 Oct 15;9(13):4674-81. Clin Cancer Res. 2003. PMID: 14581336
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: binckebanck a. Blood. 2004 Feb 15;103(4):1495-8. doi: 10.1182/blood-2003-01-0154. Epub 2003 Oct 23. Blood. 2004. PMID: 14576058 Free article. Clinical Trial.
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: binckebanck a. Blood. 2005 Jul 15;106(2):458-63. doi: 10.1182/blood-2004-05-1746. Epub 2005 Apr 7. Blood. 2005. PMID: 15817679 Free article. Clinical Trial.
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: binckebanck a. Blood. 2006 Sep 1;108(5):1469-77. doi: 10.1182/blood-2005-11-4386. Epub 2006 Apr 25. Blood. 2006. PMID: 16638934 Free article. Clinical Trial.
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG. Pfeifer H, et al. Among authors: binckebanck a. Blood. 2007 Jul 15;110(2):727-34. doi: 10.1182/blood-2006-11-052373. Epub 2007 Apr 3. Blood. 2007. PMID: 17405907 Free article.
Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D; GMALL Study Group. Ottmann OG, et al. Among authors: binckebanck a. Cancer. 2007 May 15;109(10):2068-76. doi: 10.1002/cncr.22631. Cancer. 2007. PMID: 17429836 Free article. Clinical Trial.
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gökbuget N, Binckebanck A, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: binckebanck a. Leukemia. 2002 Dec;16(12):2358-65. doi: 10.1038/sj.leu.2402770. Leukemia. 2002. PMID: 12454740 Clinical Trial.
Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Käbisch A, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: binckebanck a. Leukemia. 2003 Oct;17(10):1919-24. doi: 10.1038/sj.leu.2403093. Leukemia. 2003. PMID: 14513038 Clinical Trial.
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Wassmann B, Gökbuget N, Scheuring UJ, Binckebanck A, Reutzel R, Gschaidmeier H, Hoelzer D, Ottmann OG; GMALL Study Group. Wassmann B, et al. Among authors: binckebanck a. Ann Hematol. 2003 Nov;82(11):716-20. doi: 10.1007/s00277-003-0728-8. Epub 2003 Aug 28. Ann Hematol. 2003. PMID: 14648032 Clinical Trial. No abstract available.
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, Giagounidis A, Stelljes M, Schmalzing M, Dührsen U, Wunderle L, Serve H, Brück P, Schmidt A, Hoelzer D, Ottmann OG. Pfeifer H, et al. Among authors: binckebanck a. Leukemia. 2012 Jul;26(7):1475-81. doi: 10.1038/leu.2012.5. Epub 2012 Jan 9. Leukemia. 2012. PMID: 22230800
11 results